Details for Patent: 8,476,413
✉ Email this page to a colleague
Which drugs does patent 8,476,413 protect, and when does it expire?
Patent 8,476,413 protects INPEFA and is included in one NDA.
This patent has forty-six patent family members in twenty-eight countries.
Summary for Patent: 8,476,413
| Title: | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
| Abstract: | Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed. |
| Inventor(s): | Bryce Alden Harrison, Spencer David Kimball, Ross Mabon, David Brent Rawlins |
| Assignee: | Lexicon Pharmaceuticals Inc |
| Application Number: | US12/858,666 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,476,413
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,476,413
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2089361 | ⤷ Start Trial | 301003 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2089361 | ⤷ Start Trial | CA 2019 00042 | Denmark | ⤷ Start Trial |
| European Patent Office | 2089361 | ⤷ Start Trial | 122019000077 | Germany | ⤷ Start Trial |
| European Patent Office | 2089361 | ⤷ Start Trial | 2019C/538 | Belgium | ⤷ Start Trial |
| European Patent Office | 2089361 | ⤷ Start Trial | 42/2019 | Austria | ⤷ Start Trial |
| European Patent Office | 2089361 | ⤷ Start Trial | 132019000000113 | Italy | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
